(Alliance News) - Fusion Antibodies PLC on Friday said it expects to post double-digit growth in revenue, leading to strong expectations for the current period.
For the financial year that ended March 31, the Belfast-based antibody developer said revenue increased 14% to GBP4.8 million from GBP4.2 million the year before, through growth in all geographical regions in spite of challenges posed by the Covid-19 pandemic.
"We are pleased to have achieved revenue growth in line with expectations in what has been another challenging year globally due to the pandemic. I am delighted that the value of our client work is being demonstrated by the successes of our clients in reaching development milestones," said Chair Simon Douglas.
"The ongoing recruitment of a new CEO is progressing as planned, and we look forward to a year with more opportunities to visit clients and attend conferences as the restrictions relax. I am confident we will have a good year ahead," Douglas added.
Shares in Fusion Antibodies were down 0.4% at 65.25 pence on Friday in London.
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Fusion Antibody (FAB)